Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
COMPLETED
NCT04648969
PHASE2
Prolonged Pulsatile Kisspeptin Administration in Hypogonadotropic Hypogonadism
Sponsor: Stephanie B. Seminara, MD
View on ClinicalTrials.gov
Summary
The goal of this study is to develop novel treatments for patients with a condition called hypogonadotropic hypogonadism (HH) through the use of exogenous kisspeptin.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2019-05-03
Completion Date
2025-08-31
Last Updated
2026-08-26
Healthy Volunteers
No
Conditions
Interventions
DRUG
kisspeptin 112-121
20 intravenous doses of kisspeptin 112-121 (4 different doses of kisspeptin (randomized) in 5 sets)
DRUG
GnRH
1 intravenous dose of GnRH
Locations (1)
Massachusetts General Hospital
Boston, Massachusetts, United States